BACKGROUND: Sideroblastic anemias are heterogeneous congenital and acquired bone marrow disorders characterized by pathologic iron deposits in mitochondria of erythroid precursors. Among the congenital sideroblastic anemias (CSAs), the most common form is X-linked sideroblastic anemia, due to mutations in 5-aminolevulinate synthase (ALAS2). A novel autosomal recessive CSA, caused by mutations in the erythroid specific mitochondrial transporter SLC25A38, was recently defined. Other known etiologies include mutations in genes encoding the thiamine transporter SLC19A2, the RNA-modifying enzyme pseudouridine synthase 1 (PUS1), a mitochondrial ATP-binding cassette transporter (ABCB7), glutaredoxin 5 (GLRX5), as well as mitochondrial DNA deletions. Despite these known diverse causes, in a substantial portion of CSA cases a presumed genetic defect remains unknown. PROCEDURE: In the context of the recent discovery of SLC25A38 as a major novel cause, we systematically analyzed a large cohort of previously unreported CSA patients. Sixty CSA probands (28 females, 32 males) were examined for ALAS2, SLC25A38, PUS1, GLRX5, and ABCB7 mutations. SLC19A2 and mitochondrial DNA were only analyzed if characteristic syndromic features were apparent. RESULTS: Twelve probands had biallelic mutations in SLC25A38. Seven ALAS2 mutations were detected in eight sporadic CSA cases, two being novel. We also identified a novel homozygous null PUS1 mutation and novel mitochondrial DNA deletions in two patients with Pearson syndrome. No mutations were encountered in GLRX5, ABCB7, or SLC19A2. CONCLUSIONS: The remaining undefined probands (43%) can be grouped according to gender, family, and clinical characteristics, suggesting novel X-linked and autosomal recessive forms of CSA. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: Sideroblastic anemias are heterogeneous congenital and acquired bone marrow disorders characterized by pathologic iron deposits in mitochondria of erythroid precursors. Among the congenital sideroblastic anemias (CSAs), the most common form is X-linked sideroblastic anemia, due to mutations in 5-aminolevulinate synthase (ALAS2). A novel autosomal recessive CSA, caused by mutations in the erythroid specific mitochondrial transporter SLC25A38, was recently defined. Other known etiologies include mutations in genes encoding the thiamine transporter SLC19A2, the RNA-modifying enzyme pseudouridine synthase 1 (PUS1), a mitochondrial ATP-binding cassette transporter (ABCB7), glutaredoxin 5 (GLRX5), as well as mitochondrial DNA deletions. Despite these known diverse causes, in a substantial portion of CSA cases a presumed genetic defect remains unknown. PROCEDURE: In the context of the recent discovery of SLC25A38 as a major novel cause, we systematically analyzed a large cohort of previously unreported CSA patients. Sixty CSA probands (28 females, 32 males) were examined for ALAS2, SLC25A38, PUS1, GLRX5, and ABCB7 mutations. SLC19A2 and mitochondrial DNA were only analyzed if characteristic syndromic features were apparent. RESULTS: Twelve probands had biallelic mutations in SLC25A38. Seven ALAS2 mutations were detected in eight sporadic CSA cases, two being novel. We also identified a novel homozygous null PUS1 mutation and novel mitochondrial DNA deletions in two patients with Pearson syndrome. No mutations were encountered in GLRX5, ABCB7, or SLC19A2. CONCLUSIONS: The remaining undefined probands (43%) can be grouped according to gender, family, and clinical characteristics, suggesting novel X-linked and autosomal recessive forms of CSA. (c) 2009 Wiley-Liss, Inc.
Authors: Corinne Pondarre; Dean R Campagna; Brendan Antiochos; Lindsay Sikorski; Howard Mulhern; Mark D Fleming Journal: Blood Date: 2006-12-27 Impact factor: 22.113
Authors: Duane L Guernsey; Haiyan Jiang; Dean R Campagna; Susan C Evans; Meghan Ferguson; Mark D Kellogg; Mathieu Lachance; Makoto Matsuoka; Mathew Nightingale; Andrea Rideout; Louis Saint-Amant; Paul J Schmidt; Andrew Orr; Sylvia S Bottomley; Mark D Fleming; Mark Ludman; Sarah Dyack; Conrad V Fernandez; Mark E Samuels Journal: Nat Genet Date: 2009-05-03 Impact factor: 38.330
Authors: Jacob C Ulirsch; Jeffrey M Verboon; Shideh Kazerounian; Michael H Guo; Daniel Yuan; Leif S Ludwig; Robert E Handsaker; Nour J Abdulhay; Claudia Fiorini; Giulio Genovese; Elaine T Lim; Aaron Cheng; Beryl B Cummings; Katherine R Chao; Alan H Beggs; Casie A Genetti; Colin A Sieff; Peter E Newburger; Edyta Niewiadomska; Michal Matysiak; Adrianna Vlachos; Jeffrey M Lipton; Eva Atsidaftos; Bertil Glader; Anupama Narla; Pierre-Emmanuel Gleizes; Marie-Françoise O'Donohue; Nathalie Montel-Lehry; David J Amor; Steven A McCarroll; Anne H O'Donnell-Luria; Namrata Gupta; Stacey B Gabriel; Daniel G MacArthur; Eric S Lander; Monkol Lek; Lydie Da Costa; David G Nathan; Andrei A Korostelev; Ron Do; Vijay G Sankaran; Hanna T Gazda Journal: Am J Hum Genet Date: 2018-11-29 Impact factor: 11.025
Authors: Simon Berhe; Matthew M Heeney; Dean R Campagna; John F Thompson; Eric J White; Tristen Ross; Roy W A Peake; Jeffery D Hanrahan; Vilmarie Rodriguez; Deborah L Renaud; Mrinal S Patnaik; Eugenia Chang; Sylvia S Bottomley; Mark D Fleming Journal: Haematologica Date: 2018-07-13 Impact factor: 9.941
Authors: Gordon J Hildick-Smith; Jeffrey D Cooney; Caterina Garone; Laura S Kremer; Tobias B Haack; Jonathan N Thon; Non Miyata; Daniel S Lieber; Sarah E Calvo; H Orhan Akman; Yvette Y Yien; Nicholas C Huston; Diana S Branco; Dhvanit I Shah; Matthew L Freedman; Carla M Koehler; Joseph E Italiano; Andreas Merkenschlager; Skadi Beblo; Tim M Strom; Thomas Meitinger; Peter Freisinger; M Alice Donati; Holger Prokisch; Vamsi K Mootha; Salvatore DiMauro; Barry H Paw Journal: Am J Hum Genet Date: 2013-10-10 Impact factor: 11.025